Metropolis Healthcare reported a robust 26% year-on-year consolidated revenue growth in Q3FY26. This growth was fueled by strong performance in preventive and wellness health check-ups under TruHealth, and an increase in specialty testing volumes across both B2C and B2B channels. The company’s successful scaling of its specialty business across its pan-India network contributed significantly to the positive results.
Q3FY26 Performance Highlights
Metropolis Healthcare delivered a strong 26% year-on-year consolidated revenue growth for the quarter ended December 31, 2025 (Q3FY26). This was driven by momentum in preventive and wellness health check-ups and a strong increase in specialty testing volumes.
Key Growth Drivers
The company saw revenue growth of approximately 26% on a Y-o-Y basis. This includes revenues from Core Diagnostics, Scientific Pathology (Scientific), Agra, Dr. Ahuja’s Pathology & Imaging Center (DAPIC), Dehradun and Dr. RS Patil’s Ambika Pathology Laboratory, Kolhapur (Ambika Pathology).
TruHealth Wellness and Specialty segments recorded Y-o-Y growth of approximately 35% and 33%, respectively, in Q3FY26.
B2C revenues increased by around 18% on a Y-o-Y basis, while B2B revenue growth stood at approximately 37%.
Standalone Performance
Revenues grew by approximately 15% Y-o-Y, largely on account of increased patient and test volumes.
The Truhealth wellness segment and Specialty segment grew by approximately 23% and 16% respectively on a Y-o-Y basis.
Margin Expansion
EBITDA margins for the quarter recorded year-on-year expansion. This margin improvement highlights the resilience of the company’s operations and the strength of operating leverage embedded in its business model.
Source: BSE
